Cabergoline and bromocriptine low dose tablets are classified in this group. Cabergoline and bromocriptine tablets in higher strengths are classified in N04 - Anti-Parkinson drugs.
Lisuride tablets in high strength (0.2 mg) are classified in this group, while low strength tablets (25 mcg) are classified in N02C -
Antimigraine preparations.
The DDDs are based on use as lactation inhibitors. The DDD for parenteral depot formulations of bromocriptine is equal to the
DDD for oral administration, based on the assumption that the single dose parenteral treatment equals 14 days of oral treatment.
